Evaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapy

Basit Öğe Kaydı
dc.contributor.authorDağıstanlı, Sevinç
dc.contributor.authorSönmez, Süleyman
dc.contributor.authorBulut, Nilüfer
dc.contributor.authorKöse, Ali Mertcan
dc.date.accessioned2024-03-06T14:15:19Z
dc.date.available2024-03-06T14:15:19Z
dc.date.issued2023en_US
dc.departmentMeslek Yüksekokulları, Meslek Yüksek Okulu, Bilgisayar Teknolojileri Bölümüen_US
dc.description.abstractBackground: Breast MRIs are helpful for determining treatment plans, responses, and prospective survival analyses. In this retrospective cross?sectional study, we compared the preoperative MRI treatment response to neoadjuvant chemotherapy (NAC) administration with the postoperative pathological response in breast cancer patients. Materials and Methods: We analyzed data from 108 hospitalized patients receiving NAC between 2020 and 2022. We used MRI to evaluate the treatment response to NAC in patients with locally advanced breast cancers who had not received any prior treatment. We recorded the longest diameter of the primary tumor and the numbers of secondary tumors and axillary lymph nodes. In addition, we examined the correlation between the MRI response rate and pathological specimen results. Results: In our subgroup analyses, we found the best pathological response in patients with luminal B (Ki?67 index >14%) breast cancer and positivity for both hormone receptor and HER?2 markers. After comparing the pathological and radiological treatment responses in tumors and lymph nodes, the sensitivities were 90.3% for the pathological assessment and 42.8% for the radiological assessment, while the accuracies were 84.2% for the pathological assessment and 61.1% for the radiological assessment. Conclusion: Using MRI techniques and sequence intervals and examining the histopathological characteristics of tumors may help increase the accuracy of the pathological complete response.en_US
dc.identifier.doi10.4103/jcrt.jcrt_1409_22en_US
dc.identifier.endpage826en_US
dc.identifier.issue(Suppl 2)en_US
dc.identifier.pmid38384061en_US
dc.identifier.scopus2-s2.0-85185790475en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage821en_US
dc.identifier.urihttps://hdl.handle.net/11467/7162
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1409_22
dc.identifier.volume19en_US
dc.identifier.wosWOS:001191041600058en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast cancer, MRI, pathological responseen_US
dc.titleEvaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
evaluation_of_treatment_responses_among_subgroups.58.pdf
Boyut:
742.98 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.56 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu